Zobrazeno 1 - 10
of 21
pro vyhledávání: ''
Autor:
Jong Wan Park, Younghoon Kim, Yong-Sung Juhnn, Sung Jin Cho, Jae Seon Lee, Young San Ko, Seon Young Nam, Jae Seung Kang, Byung Lan Lee, Woo Ho Kim
Publikováno v:
Cancer Science. 99:1117-1124
The role of nuclear factor-kappaB (NF-kappaB) activation in cancer cell apoptosis appears to be tailored specifically for each cell type and the type of NF-kappaB inducer. The present study aimed to determine whether or not NF-kappaB activation is as
Publikováno v:
Cancer Science. 99:1209-1217
In the present study, irinotecan (CPT-11) was highly effective not only against the chemosensitive neuroblastoma (NB) xenografts SK-N-ASnu and TNB9, but also against the multidrug-resistant NB xenograft TS-N-2nu. SK-N-ASnu and TNB9 were significantly
Publikováno v:
Cancer Science. 99:863-871
When a replicative DNA polymerase encounters a lesion on the template strand and stalls, it is replaced with another polymerase(s) with low processivity that bypasses the lesion to continue DNA synthesis. This phenomenon is known as translesion repli
Autor:
Hiroto Izumi, Ryuichi Okayasu, Naoya Miyamoto, Kazuo Chijiiwa, Masaki Shiota, Takamitsu Onitsuka, Ichiro Niina, Tomonori Igarashi, Kimitoshi Kohno, Takeshi Uchiumi, Tetsuro Wakasugi, Takayuki Torigoe
Publikováno v:
Cancer Science. 98:858-863
Modification of transcription factors by anticancer agents plays an important role in both apoptotic and survival signaling. Here we report that both DNA topoisomerase I and II inhibitors such as SN-38 and etoposide, but not cisplatin, 5-fluorouracil
Publikováno v:
Cancer Science
Three-dimensional (3D) cell culture is beneficial for physiological studies of tumor cells, due to its potential to deliver a high quantity of cell culture information that is representative of the cancer microenvironment and predictive of drug respo
Autor:
Chie Nishioka, Takayuki Ikezoe, Hirokuni Taguchi, Takahiro Taguchi, Yang Yang, Wei-Guo Zhu, H. Phillip Koeffler
Publikováno v:
Cancer Science. 97:1404-1409
ZD6474 (Zactima, AstraZeneca, Macclesfield, UK) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinases, with additional activity versus rearranged during
Autor:
Yoshihiro Kikuchi, Yoichi Kobayashi, Isamu Ishiwata, Nao Suzuki, Kazushige Kiguchi, Tsunekazu Kita, Bunpei Ishizuka, Yuriko Iwamori, Masao Iwamori
Publikováno v:
Cancer Science. 97:1321-1326
The transporter protein genes and lipids in human ovarian carcinoma-derived KF28 cells with anticancer-drug-sensitive properties were compared with those in resistant cells, taxol-resistant KF28TX, cisplatin-resistant KFr13, and taxol- and cisplatin-
Autor:
Misako Haraguchi, Shin-ichi Akiyama, Hiroshi Okumura, Yasuo Takeda, Hei Cheul Jeung, Tatsuhiko Furukawa, Mina Ushiyama, Katsushi Yamada, Yoshihiko Shibayama, Ryuji Ikeda, Chun-Lei Zheng, Tomoyuki Sumizawa, Xiao-Fang Che, Tatsuya Yamaguchi, Kazuo Nakamura
Publikováno v:
Cancer Science. 96:372-376
A major impediment to cancer treatment is the development of resistance by the tumor. P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP1) are involved in multidrug resistance. In addition to the extrusion of chemotherapeutic agents throug
Autor:
Hideki Mizutani, Yusuke Hiraku, Michio Kojima, Takuya Iwamoto, Shosuke Kawanishi, Shinji Oikawa
Publikováno v:
Cancer Science. 95:454-458
In this study, we compared the DNA-damaging ability of bifunctional busulfan and monofunctional ethyl methanesulfonate (EMS, CH3SO2OC2H5) and their cytotoxicity towards human promyelocytic leukemia HL-60 cells. We also investigated the site specifici
Autor:
Yoshinobu Hirose, Takuji Tanaka, Toshiya Kuno, Masaki Katayama, Hiroyuki Kohno, Koujiro Yoshida, Zheng Qiao, Toshiyuki Shibata, Shigeyuki Sugie, Yasuhiro Yamada, Keiko Sakata, Hideki Mori
Publikováno v:
Cancer Science. 94:365-371
Ligands for peroxisome proliferator-activated receptor (PPAR) γ have been implicated in growth inhibition and cell differentiation in certain malignancies. In this study, the effects of troglitazone, a PPARy ligand, given during the postinitiation p